EN ▾
SNAPE REP RT Front page →
ConfirmedMedicine17 Nov, 12:06 UTC

Isomorphic Labs raises $5 billion to take AI-designed drugs toward clinical trials

Isomorphic Labs founder Demis Hassabis, photographed for TechCrunch
Getty Images via TechCrunch

The Alphabet drug-discovery unit's Series C was co-led by Greenoaks and Sequoia, with Andreessen Horowitz joining as a new investor.

Read at TechCrunch Share

Why it matters

Isomorphic was spun out of DeepMind to turn AlphaFold-style protein modelling into medicines. The new money is meant to move its own candidates into human trials, a step no AI-first drug company has yet turned into an approved drug. It also has partnerships with Eli Lilly, Novartis and Johnson & Johnson.

Key facts

  • $5 billion Series C
  • Co-led by Greenoaks and Sequoia; a16z is new
  • Backers include GV, Thrive, MGX and Temasek
  • Partnerships with Eli Lilly, Novartis and J&J

Sources

More on Medicine
More from Snape ReportFront page →